Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Cholinesterase inhibitors remain the long-standing pharmacologic standard in Alzheimer's disease, yet their measured effect on cognition is modest and does not alter the underlying course of neurodegeneration. The distinction between temporarily supporting neurotransmission and preserving neuronal tissue defines both the ceiling of these drugs and the case for addressing modifiable risk decades earlier.
Deep Longevity will launch Accrua, a US telehealth platform that anchors prescriptions for GLP-1 agonists, peptides and hormone therapy to a blood-based biological age score rather than symptoms alone, with quarterly re-testing. The underlying model draws on a cohort of roughly 2,600 adults followed for 9.2 years, in which each year of gap between biological and chronological age corresponded to a 15% increase in mortality risk. Predictive validity is not the same as treatment utility, and no outcome data yet show that prescribing guided by the score improves results.
A fatty acid produced by the gut bacterium Bacteroides uniformis — pentadecanoic acid (C15:0) — reduced atherosclerotic plaque burden and circulating LDL cholesterol in mice prone to arterial disease. The mechanism runs through the liver: the molecule suppresses hepatic cholesterol synthesis, which activates SREBP2 and upregulates LDL receptors to clear more cholesterol from the blood. Effects were slightly weaker than atorvastatin, and the study measured slowed progression rather than plaque reversal.
AgelessRx has released a prescription copper peptide (GHK-Cu) cream in two compounded strengths, 0.5% and 3%, intended to support skin repair processes that decline with age. Each prescription requires review by a licensed provider, and the company reports 99.8% purity alongside microbial and endotoxin testing; compounded formulations are not FDA-approved. The launch places a well-characterized endogenous peptide into a clinician-supervised dosing model rather than an over-the-counter cosmetic one.
Across two large longitudinal cohorts totaling more than 468,000 adults in Israel and a matched US network, serum 25-hydroxyvitamin D below 10 ng/mL was associated with substantially higher all-cause mortality (adjusted HR 2.57 and 1.59) and elevated risk across metabolic, cardiovascular, renal, neurodegenerative, and microvascular outcomes. Pharmacy-dispensed supplementation modeled longitudinally showed dose-dependent risk reduction, with a mortality hazard ratio of 0.72 for exposure equivalent to raising serum levels by more than 10 ng/mL. Marginal structural Cox models with inverse-probability weighting produced results consistent with conventional adjustment, strengthening the case for a modifiable contribution.
Male mice and humans show accelerated immune aging in midlife, marked by earlier thymic involution, contraction of lymph node structure, and a steeper decline in naive CD8+ T cells. The reduced naive repertoire impairs recognition of tumor antigens and weakens responses to checkpoint immunotherapy, identifying middle age as the point at which sex-divergent immune surveillance begins to matter clinically.
Novartis' President of Biomedical Research, Fiona Marshall, outlines a research strategy that treats aging as the principal upstream driver of cardiovascular, neurodegenerative, and oncologic disease, targeting mitochondrial dysfunction, declining DNA repair, and extracellular matrix alterations. The stated ambition shifts from decelerating decline to restoring healthy tissue. Marshall also proposes stratifying patients by 'aging endotypes' — dominant biological drivers such as inflammation, metabolic dysfunction, or impaired DNA repair — identified through proteomic signatures.
ProMIS Neurosciences has appointed Ivana Rubino, Ph.D., as chief commercial officer to lead market access, payer strategy and launch readiness for PMN310, a humanized monoclonal antibody engineered to bind toxic amyloid-beta oligomers while sparing monomers and deposited plaque. The candidate is in the PRECISE-AD Phase 1b study, with unblinded 12-month topline data expected in the first quarter of 2027. The selectivity profile is intended to separate therapeutic effect from the off-target binding associated with earlier amyloid-directed antibodies.
Maze Therapeutics will present updated Phase 2 HORIZON data for MZE829, a dual-mechanism APOL1 inhibitor, in adults with APOL1-mediated kidney disease, alongside preclinical work on the SLC6A19 inhibitor MZE782. The company describes SLC6A19 inhibition as reducing nephrotoxin uptake and promoting a protective metabolic state in the proximal tubule, complementary to SGLT2 inhibition. Both programs target genetically and metabolically defined mechanisms of renal decline rather than downstream blood pressure or glycemic control.
An eight-week preclinical study in diabetic db/db mice reported that daily oral Tazbentetol preserved retinal ganglion cell function and survival, restored synaptic protein expression, reduced markers of gliosis and cell death, and improved optic nerve myelination. According to the company, these effects occurred without changes in blood glucose, insulin resistance or body weight, implying a neuroprotective mechanism independent of metabolic control. Electrophysiological measures, including pattern electroretinogram amplitude and visual evoked potential latency, moved toward normal values.
Bexorg received up to $28.3 million from ARPA-H to extend its BrainEx ex vivo brain perfusion platform from 24 hours to as long as two weeks across a three-phase, 36-month program. The extended window would permit repeated dosing and sustained drug exposure in intact human brain tissue, capturing pharmacological mechanisms that only emerge beyond a single day. Longitudinal multi-omics datasets generated this way are intended to inform dosing strategy, biomarker selection and trial design for Alzheimer's disease and other central nervous system conditions.
A Frontiers in Aging analysis identifies Bolotana, a Sardinian village of roughly 2,262 residents, as a blue zone with ten verified centenarians — about 442 per 100,000, some ten times the Sardinian average. Women who reached 70 had a 13.83% chance of reaching 100 versus 4.92% for men, a gender gap wider than observed elsewhere. The village has no gym, no fast food, and a traditional diet that was roughly 90% plant-based.